edifoligide

Edifoligide is a double-stranded oligodeoxynucleotide (ODN) that acts as a transcription factor decoy, specifically inhibiting the E2F family of transcription factors. By mimicking the consensus binding sequence for E2F, edifoligide competitively binds to and inhibits these transcription factors, thereby reducing their activation of cell cycle genes involved in smooth muscle cell proliferation. This mechanism was intended to prevent neointimal hyperplasia—a key cause of vein graft failure—following vascular bypass procedures such as coronary artery bypass graft (CABG) surgery and lower extremity bypass. Edifoligide was administered ex vivo to harvested vein grafts before implantation using a pressure-mediated delivery system, minimizing systemic exposure. Despite promising early-phase results showing inhibition of neointimal hyperplasia and good safety profiles, large phase 3 trials did not demonstrate efficacy in preventing vein graft failure or improving long-term clinical outcomes compared with placebo[2][3][5][6].

Other names

edifoligide sodium